It is anticipated that individual treatment arms will be closed and added during the conduct of the study as arms complete accrual, individual arm safety data is analyzed, and new arms are added. Initially, three arms are proposed in Phase 2: durvalumab plus BCG, durvalumab plus EBRT, and BCG re-treatment. Enrollment to Phase 2 arms will not begin until at least one arm has successfully completed the Phase 1 safety evaluation and deemed safe to proceed to the Phase 2 portion of the trial.